Petauri Expands Its Leadership Team with Mark Levonyak as EVP of New Business

Petauri Welcomes Mark Levonyak as Executive Vice President

Petauri, a prominent name in the pharmaceutical services industry, has made a significant addition to its leadership team with the recent appointment of Mark Levonyak as Executive Vice President of New Business. This announcement comes as the company aims to enhance its strategic direction and drive further growth within its medical communications division, particularly under Petauri Advance.

A Rich Background in Pharmaceutical Services

With an impressive career spanning 39 years, Mark Levonyak brings a wealth of experience in drug development, clinical operations, and medical affairs. His previous role as Executive Vice President and Executive Clinical Strategist at Vaniam Group, LLC, showcased his capability in developing and managing multiple business units. Furthermore, his leadership as President at DAVA Oncology, LLC, coupled with several C-suite roles at AnorMED and Cell Therapeutics, reflects his deep expertise in the pharmaceutical and biotech realms.

Dan Renick, CEO of Petauri, expressed enthusiasm about Levonyak's joining, noting that his extensive background in medical communications is crucial for advancing Petauri's mission. Renick stated, "We are thrilled to welcome Mark Levonyak to Petauri. His extensive experience will be instrumental in driving our mission forward, and we are confident that he will help us take our agencies to new heights."

Focusing on Strategic Growth and Innovation

In his new role, Levonyak will steer the strategic direction of new business activities, aiming to commercialize both existing products and services, along with introducing innovative solutions to the marketplace. When reflecting on his new opportunity, Levonyak expressed excitement about collaborating with the talented teams at Petauri. He remarked, "I look forward to expanding our medical communication therapeutic expertise while leveraging our collective strengths to achieve remarkable success in the industry."

Petauri's Vision and Initiatives

Founded in 2023, Petauri has swiftly established itself as a purpose-built pharmaceutical services platform based in Nashville, Tennessee. The company focuses on launching, acquiring, and integrating best-in-class firms recognized for their expertise in various areas, including global market access and patient services.

Notably, Petauri has already launched Petauri Advisors and acquired multiple agencies to enhance its service offerings. This initiative is supported by an ambitious commitment of over $250 million in equity capital from Oak Hill, ensuring that Petauri remains a key player in pharmaceutical advancement.

By connecting scientific, economic, and humanistic aspects of medical developments, Petauri strives to improve patient outcomes systematically. Their approach encompasses everything from strategy formulation to implementation, allowing for speedy access to life-changing care.

For further details about Petauri and its multitude of services, interested parties can visit the official website at www.petauri.com.

In conclusion, Mark Levonyak's appointment marks a significant step for Petauri as it continues to innovate and expand within the pharmaceutical services landscape.